Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 2, 2019
Arcturus Therapeutics to Present at Three Upcoming Investor Conferences
SAN DIEGO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (ARCT), a leading messenger RNA medicines company focused on the discovery, ...
October 2, 2019
Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advanced Bone Graft MagnetOs
SCHLIEREN (ZURICH), Switzerland, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences, (KURN.SW) a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration, ...
September 30, 2019
OSE Immunotherapeutics Presents New Preclinical Data on its Novel Bispecific Checkpoint Inhibitor (BiCKI®) Platform Targeting PD-1 and Cytokines to Overcome Tumor Resistance to Checkpoint Inhibitor Blockade
NANTES, France, Sept. 30, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Euronext: OSE) presented new data on its BiCKI® platform at the International Cancer ...
September 30, 2019
TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer
NEW YORK, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that ...
September 30, 2019
Vermillion to Participate at 2019 Cantor Global Healthcare Conference
AUSTIN, Texas, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that management will ...
September 30, 2019
Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa
NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will be attending the 2019 Cell & Gene ...
September 30, 2019
UroGen To Present at October 2019 Investor Conference
NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will present at ...
September 30, 2019
Krystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference
PITTSBURGH, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients ...
September 30, 2019
electroCore Appoints Medical Technology Veteran Daniel S. Goldberger as Chief Executive Officer
BASKING RIDGE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Daniel S. Goldberger ...
September 30, 2019
Further Data Review Shows Major Clinical Benefits From Veyonda®
SYDNEY, Australia, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Noxopharm (NOX.AX) further describes the upcoming release of clinical data concerning its lead drug candidate, Veyonda®. On ...
September 30, 2019
HTG Molecular to Present Corporate Overview at the Cantor 2019 Global Healthcare Conference
TUCSON, Ariz., Sept. 30, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today ...
September 30, 2019
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma
CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively ...
September 30, 2019
First Biopsy Confirmed Nash Patient Dosed In Lipocine LiFT Study Of LPCN 1144
SALT LAKE CITY, Sept. 30, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the ...
September 30, 2019
CymaBay Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies ...
September 30, 2019
Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress
FLORHAM PARK, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs ...
September 30, 2019
Neovasc's Tiara™ for Treatment of Mitral Regurgitation and Neovasc Reducer™ for Treatment of Refractory Angina Featured in Multiple Presentations at TCT 2019 Conference
VANCOUVER , Sept. 30, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter ...
September 30, 2019
Albireo Announces Presentations at NASPGHAN 2019 Annual Meeting
BOSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
September 30, 2019
Total number of shares and voting rights in Zealand Pharma at September 30, 2019
Copenhagen, September 30, 2019 – Zealand Pharma A/S (“Zealand”) (ZEAL.CO) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development ...
September 30, 2019
AB Science today reports its revenues for the first half of 2019 and provides an update on its activities
AB Science SA (NYSE Euronext - FR0010557264 - AB) today reports its revenues for the first half of 2019 and provides an update on its ...
September 30, 2019
Inventiva completes a capital increase of € 625,000 subscribed by Sofinnova Partners through Sofinnova Crossover I Fund
Daix (France), September 30th, 2019 – Inventiva (IVA.NX), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas ...
Page 5 of 169